Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 18/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | POU2F2 | P09086 | 1/20 | 0.42 |
| ▸ | POU2F1 | P14859 | 1/20 | 0.42 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30445113 | 0.90 | KCNJ1 (0.48) | KCNJ1KCNH2ABCB11POU2F2POU2F1 | |
| SCHEMBL20168335 | 0.90 | KCNJ1 (0.48) | KCNJ1KCNH2ABCB11POU2F2POU2F1 | |
| SCHEMBL24135397 | 0.85 | KCNJ1 (0.47) | KCNJ1KCNH2ABCB11POU2F2POU2F1 | |
| SCHEMBL20176738 | 0.79 | KCNJ1 (0.41) | KCNJ1KCNH2ABCB11POU2F2POU2F1 | |
| SCHEMBL23586685 | 0.76 | KCNJ1 (0.57) | KCNJ1KCNH2ABCB11POU2F2POU2F1 | |
| SCHEMBL30444639 | 0.76 | KCNJ1 (0.52) | KCNJ1KCNH2ABCB11POU2F2POU2F1 | |
| SCHEMBL20168367 | 0.76 | KCNJ1 (0.52) | KCNJ1KCNH2ABCB11POU2F2POU2F1 | |
| SCHEMBL28362242 | 0.76 | KCNJ1 (0.43) | KCNJ1KCNH2ABCB11POU2F2POU2F1 | |
| SCHEMBL20168011 | 0.75 | KCNJ1 (0.42) | KCNJ1KCNH2ABCB11POU2F2POU2F1 | |
| SCHEMBL21266181 | 0.75 | KCNJ1 (0.42) | KCNJ1KCNH2ABCB11POU2F2POU2F1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10723723-B2 | Substituted bicycle heterocyclic derivatives useful as ROMK channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-07-28 | — | — | US | disclosed |
| US-20190248769-A1 | SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10723723-B2 | Substituted bicycle heterocyclic derivatives useful as ROMK channel inhibitors | KCNB1, CACNA1E, GRK1 | KCNJ1 85/4885KCNH2 53/4885ABCB11 690/4885 |
| US-20190248769-A1 | SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS | KCNB1, CACNA1E, GRK1 | KCNJ1 85/4885KCNH2 53/4885ABCB11 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.